ClinicalTrials.gg
Not yet recruitingNCT07274683Updated Oct 27, 2026

Stellate Ganglion Block on Postoperative Sleep Status in Patients With Prolonged Disorders of Consciousness

An interventional study of stellate ganglion block with 0.5% ropivacaine in Stellate Ganglion Block, Prolonged Disorders of Consciousness and Sleep, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Other

How we know

Updated Oct 27, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Consciousness Disorders with a site in China — 30 open to participants now, 31 under way, 1 of them phase 3. Consciousness Disorders · China.

Planned enrollment
35th of 40
25 · median 60
Started
2026
with 7 others
No phase
36 of 70
18 open now
Primary completion
2027-07
later than 24 of 30 live
Registered
65th of 70
by date
Lead sponsor
7 of 70
Beijing Tiantan Hospital

Among the 70 studies in Consciousness Disorders with a site in China, this one is the 35th largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 24 of the 30 other live ones, and was the 65th registered.

Consciousness Disorders

291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

Browse Consciousness Disorders studies →

Open to participants now

30 of the 70 studies in Consciousness Disorders with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Consciousness Disorders with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-centre, single-arm, self-controlled, exploratory pilot study.

The goal of this clinical trial is to learn about the effect of preoperative administration of stellate ganglion block on postoperative sleep status in patients with prolonged disorders of consciousness. The main aims to answer are: To explore the feasibility and safety of unilateral SGB in pDOC patients, evaluate its impact on sleep time and sleep architecture from the preoperative night to the night of surgery, compare the cerebral hemodynamic parameters, cerebral oxygen saturation and Coma Recovery Scale-Revised (CRS-R) scores in pDOC patients before and after SGB, and inform the design and sample size calculation of a future definitive RCT.

Participants will be pDoC patients with intact skulls after acquired brain injury who will undergo spinal cord electronic stimulator implantation under general anesthesia at Beijing Tiantan Hospital. Stellate ganglion block will be administrated before the surgery. Polysomnography, total sleep time, cerebral oxygen saturation, cerebral hemodynamic parameters, CRS-R scores will be investigated.

03

Conditions studied

  • Stellate Ganglion Block
  • Prolonged Disorders of Consciousness
  • Sleep
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-65 years;
  • Prolonged disorders of consciousness after acquired brain injury;
  • Scheduled to undergo spinal cord electronic stimulator implantation under general anesthesia;
  • The skull is intact;
  • is obtained;

Exclusion criteria

Exclusion Criteria:

  • Continuous sedation therapy is performed within 72 hours prior to the study;
  • The integrity of brain structure is disrupted due to causes such as open head injury and cerebral parenchymal resection;
  • Decreased intracranial compliance caused by hydrocephalus and other reasons;
  • Airway stenosis or severe dysfunction of ventilation or gas exchange due to various causes;
  • Known or suspected severe cardiac, pulmonary, and renal dysfunction;
  • History of sedative drug allergy;
  • Complicated by other mental or neurological disorders;
  • Local anesthetic allergy;
  • Other reasons for ineligibility in this study;
  • is not obtained;
  • Pregnant or lactating women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    stellate ganglion block

    preoperative administration of stellate ganglion block

    Drug: stellate ganglion block with 0.5% ropivacaine

Interventions

  • Drugstellate ganglion block with 0.5% ropivacaine

    A single dose of ultrasound-guided stellate ganglion block with 0.5% ropivacaine was administered to the pDoC patients after induction of general anesthesia but before surgical incision.

06

What researchers measure

Primary outcomes

  1. The change in total sleep time

    total sleep time on PSG

    Time frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)

Secondary outcomes

  1. sleep structure before and after SGB

    sleep structure will be measured using polysomnography (PSG)

    Time frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)

  2. sleep latencies before and after SGB

    sleep latencies will be measured using polysomnography (PSG)

    Time frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)

  3. sleep stage distribution before and after SGB

    sleep stage distribution will be measured using polysomnography (PSG)

    Time frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)

  4. Change in cerebral oxygen saturation

    Regional cerebral oxygen saturation (rSO₂) measured by near-infrared spectroscopy (NIRS).

    Time frame: 30 minutes after stellate ganglion block

  5. Change in cerebral hemodynamic parameters

    cerebral hemodynamic parameters measured by Transcranial Doppler(TCD)

    Time frame: 30 minutes after stellate ganglion block.

  6. the recovery of consciousness

    Consciousness recovery will be assessed using the Coma Recovery Scale-Revised (CRS-R). It assesses patients across six functional domains: auditory, visual, motor, oromotor/verbal, communication, and arousal. The total score ranges from 0 to 23, with higher scores indicating a higher level of consciousness.

    Time frame: 1 and 30 days postoperatively

  7. Length of ICU stay

    Time frame: 30 days postoperatively

  8. Costs of ICU stay

    Time frame: 30 days postoperatively

  9. Safety outcomes

    SGB-related complications and unanticipated adverse events

    Time frame: 30 days postoperatively

  10. Feasibility outcomes

    Time frame: 30 days postoperatively

  11. SGB success rate

    Time frame: 30 days postoperatively

  12. PSG data completeness

    Time frame: 30 days postoperatively

  13. adverse event rate

    Time frame: 30 days postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All data generated or analysed during this study will be included in published article. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Access criteria: The data that support the findings of this study are available from the corresponding author upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.

Of 90 non-industry interventional studies with no phase under Consciousness Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 64. This study's planned 9 months is below that.

Counting every sponsor, half of 95 studies reached it within 19 months; a quarter within 8 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jan 2026 → Oct 2026, primary completion Jul 2026 → Jul 2027 and completion Jan 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2025
First posted
Dec 10, 2025
StartEst.
Oct 2026was Jan 2026
Primary completionEst.
Jul 2027was Jul 2026
CompletionEst.
Dec 2027was Jan 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 1, 2026→Oct 2026
Oct 27, 2026
Primary completion
Jul 1, 2026→Jul 2027
Oct 27, 2026
Study completion
Jan 1, 2027→Dec 2027
Oct 27, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedPregnant or lactating women
Oct 27, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTotalThe change in total sleep timeTime frame: on the first postoperative night → from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
Oct 27, 2026
Secondary outcomes
2 edited, 8 added
What changed in the outcomes
  • EditedChange in cerebral oxygen saturationTime frame: 30 minutes after stellate ganglion block
  • EditedChange in cerebral hemodynamic parametersTime frame: 30 minutes after stellate ganglion block.
  • Addedsleep structure before and after SGBTime frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
  • Addedsleep latencies before and after SGBTime frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
  • Addedsleep stage distribution before and after SGBTime frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
  • AddedSafety outcomesTime frame: 30 days postoperatively
  • AddedFeasibility outcomesTime frame: 30 days postoperatively
  • AddedSGB success rateTime frame: 30 days postoperatively
  • AddedPSG data completenessTime frame: 30 days postoperatively
  • Addedadverse event rateTime frame: 30 days postoperatively
Oct 27, 2026
Design
Study type Observational→Interventional
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Jan 1, 2026→Oct 2026
    Primary completion Jul 1, 2026→Jul 2027
    Study completion Jan 1, 2027→Dec 2027
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedPregnant or lactating women
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTotalThe change in total sleep timeTime frame: on the first postoperative night → from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
    Secondary outcomes 2 edited, 8 added
    What changed in the outcomes
    • EditedChange in cerebral oxygen saturationTime frame: 30 minutes after stellate ganglion block
    • EditedChange in cerebral hemodynamic parametersTime frame: 30 minutes after stellate ganglion block.
    • Addedsleep structure before and after SGBTime frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
    • Addedsleep latencies before and after SGBTime frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
    • Addedsleep stage distribution before and after SGBTime frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
    • AddedSafety outcomesTime frame: 30 days postoperatively
    • AddedFeasibility outcomesTime frame: 30 days postoperatively
    • AddedSGB success rateTime frame: 30 days postoperatively
    • AddedPSG data completenessTime frame: 30 days postoperatively
    • Addedadverse event rateTime frame: 30 days postoperatively
    Design Study type Observational→Interventional
    + 5 other changes: identifiers, verification date, oversight details, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07274683
Responsible party
Ruquan Han (Director, Beijing Tiantan Hospital) — Principal investigator
First posted
Dec 10, 2025
Start date
Oct 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Minyu Jian
Contact
yum1988@163.com
+8613522550438

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion